Bempedoic Acid

證據等級: L5

預測適應症: 10 個

Bempedoic Acid: From Hypercholesterolemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Bempedoic acid is an ATP-citrate lyase (ACL) inhibitor approved in the US and EU for lowering LDL-cholesterol in adults with hypercholesterolemia or mixed dyslipidemia. Among the 10 TxGNN-predicted new indications evaluated, Homozygous Familial Hypercholesterolemia (HoFH) emerges as the most actionable candidate—it sits within the same lipid-lowering pathway as the drug’s established indication and is the only prediction with real clinical evidence. 17 publications support this direction, including a 2026 real-world retrospective cohort specifically evaluating bempedoic acid in HoFH patients.

Note on prediction selection: TxGNN’s highest-scored prediction (hyperthyroidism, score 99.61%) lacks any established mechanistic link to ACL inhibition and has only one tangentially related publication. Several other top predictions (e.g., infectious bovine rhinotracheitis, malignant catarrh) refer to veterinary diseases with no human relevance. HoFH (TxGNN score 99.48%) is selected as the primary focus of this report because it is the only prediction with substantive human clinical evidence (L3) and a coherent pharmacological rationale.

Quick Overview

Item	Content
Original Indication	Hypercholesterolemia / LDL-C reduction (not registered in India)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.48% (global rank 8,682)
Evidence Level	L3 – Observational study + multiple systematic reviews
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Bempedoic acid is a liver-targeted prodrug. After oral absorption, it is activated exclusively in hepatocytes by the enzyme very-long-chain acyl-CoA synthetase-1 (ACSVL1) into its active form, ETC-1002-CoA. This active metabolite inhibits ATP-citrate lyase (ACL), an enzyme that sits one step upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. By blocking ACL, bempedoic acid reduces the liver’s internal cholesterol production, which triggers a compensatory upregulation of LDL receptor (LDLR) expression on hepatocyte surfaces—leading to increased removal of LDL particles from the bloodstream.

HoFH is caused by biallelic mutations in the LDLR gene, resulting in severely impaired or essentially absent LDL receptor function. This presents an important mechanistic caveat: because bempedoic acid’s LDL-lowering effect partly depends on functional LDLR to clear circulating LDL-C, the benefit in HoFH patients with complete receptor loss will be attenuated. However, in patients with residual LDLR activity—particularly in compound heterozygotes rather than true null-null genotypes—meaningful LDL-C reduction remains plausible. Additionally, when bempedoic acid is added to LDLR-independent agents such as evinacumab (an ANGPTL3 inhibitor) or lomitapide (an MTP inhibitor), it may contribute a complementary reduction on top of an already aggressive regimen.

This prediction is best understood as a pharmacologically logical label extension along the familial hypercholesterolemia spectrum. Bempedoic acid already holds approval for heterozygous FH (HeFH)—the same disease at a less severe degree. HoFH sits at the extreme end of that same LDL-pathway disorder. A 2026 real-world study (Warden & Duell, PMID 41274797) published in the Journal of Clinical Lipidology directly evaluated bempedoic acid use in HoFH patients, confirming that clinical practice is already exploring this extension ahead of formal regulatory approval.

Clinical Trial Evidence

Currently no clinical trials are registered for bempedoic acid specifically in homozygous familial hypercholesterolemia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41274797	2026	Real-world retrospective cohort	Journal of Clinical Lipidology	Direct evaluation of bempedoic acid efficacy and tolerability in HoFH patients; the only study focused specifically on this population
41741298	2026	Clinical consensus	Journal of Clinical Lipidology	National Lipid Association expert consensus on FH; addresses HoFH management including adjunct role of bempedoic acid
41106315	2025	Review	Experimental and Molecular Pathology	Comprehensive review of novel therapies for HoFH, including ACL inhibition; discusses LDL-receptor–independent mechanisms
39070027	2024	Review	American Journal of Preventive Cardiology	LDL-C targeting beyond PCSK9 inhibitors; positions bempedoic acid within the broader lipid-lowering landscape
38576462	2024	Review	American Journal of Preventive Cardiology	Cumulative lifetime LDL-C exposure and ASCVD prevention; emphasises early, aggressive LDL lowering relevant to HoFH
37071085	2024	Drug review / approval	Cardiology in Review	Evinacumab approval review for HoFH; contextualises bempedoic acid as a potential add-on therapy in combination regimens
37979722	2024	Review	Indian Heart Journal	Non-statin lipid-lowering drugs including bempedoic acid; directly relevant to India clinical practice context
35466160	2022	Review	Journal of Atherosclerosis and Thrombosis	Advances in HoFH treatment; discusses bempedoic acid as adjunct alongside lomitapide, evinacumab, and LDL apheresis
35754818	2022	Review	Frontiers in Genetics	Refractory hypercholesterolemia and emerging gene therapies; bempedoic acid discussed as a bridging/combination agent
29449335	2018	Preclinical (animal model)	Arteriosclerosis, Thrombosis, and Vascular Biology	Bempedoic acid significantly lowered LDL-C and reduced atherosclerotic burden in LDLR-deficient Yucatan miniature pigs—a direct large-animal model of HoFH

India Market Information

Bempedoic acid is not currently registered in India. No CDSCO-approved products are on record. This means that any development pathway toward HoFH would first require establishing the base hypercholesterolemia/HeFH indication in India before pursuing a label extension to HoFH.

Safety Considerations

Detailed safety data from the Indian package insert were not available in this Evidence Pack.

Pregnancy safety concern: Bempedoic acid has demonstrated fetal toxicity in animal reproductive studies and is contraindicated during pregnancy. This is a critical consideration that immediately eliminates the separately TxGNN-predicted indication of “pregnancy-associated osteoporosis” (TxGNN rank 10) from further evaluation—not only does the prediction lack mechanistic support, but it carries an absolute safety contraindication.

Please refer to the approved prescribing information (US/EU labels are publicly available) for complete warnings, contraindications, and drug interaction data pending full India package insert retrieval.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: HoFH shares the same lipid metabolic pathway as bempedoic acid’s established indication, making this a scientifically coherent label extension. A 2026 real-world cohort provides the first direct clinical evidence in HoFH patients, and multiple expert reviews already position bempedoic acid within HoFH combination regimens. The key pharmacological limitation—LDLR dependency—is real but does not eliminate all patient subgroups from potential benefit.

To proceed, the following is needed:

Retrieve full MOA and safety data: Query DrugBank API for complete mechanistic details; download the CDSCO/FDA package insert to fill the safety data gap (currently blocking S1 evaluation)
India regulatory pathway: Bempedoic acid has zero registrations in India; establishing a base hypercholesterolemia indication with CDSCO is a prerequisite before any HoFH label extension can be pursued
Patient subgroup definition: Prioritise HoFH patients with residual LDLR activity (compound heterozygotes, missense mutations) over complete null-null genotypes, where the pharmacological rationale is strongest
Evidence upgrade: No clinical trials exist; a prospective registry study or Phase 2 pilot in Indian HoFH patients would significantly strengthen the evidence base (India’s consanguineous population structure may produce a higher-than-average HoFH prevalence in certain communities)
Combination strategy design: Evaluate bempedoic acid as add-on to LDLR-independent agents (evinacumab, lomitapide) rather than as monotherapy in HoFH
Uric acid monitoring: Bempedoic acid is known to raise serum urate; gout risk monitoring should be incorporated into any HoFH treatment protocol
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.